272
Participants
Start Date
September 30, 2014
Primary Completion Date
September 30, 2016
Study Completion Date
October 31, 2016
PF-02545920
20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
PF-02545920
5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
Placebo
Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
Charite - Universitatsmedizin Berlin, Berlin
Albany Medical College, Albany
Universitat zu Lubeck, Lübeck
Wake Forest Baptist Medical Center - Dept. of Neurology, Winston-Salem
Krakowska Akademia Neurologii Sp. z o.o., Krakow
University of Florida Center for Movement Disorders and Neurorestoration, Gainesville
Philipps Universitat Marburg, Marburg
The Kirklin Clinic of UAB Hospital, Birmingham
The University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, Birmingham
Davis Medical Center, Columbus
The Wexner Medical Center at the Ohio State University, Columbus
Wexner Medical Center at the Ohio State University, Columbus
Cleveland Clinic Foundation Hospital Pharmacy, Cleveland
The Cleveland Clinic Foundation, Cleveland
Prof. Dr. Carsten Saft, Bochum
Indiana University Health Neuroscience Center, Indianapolis
George Huntington Institut, Münster
Uniklinik RWTH Aachen, Aachen
Solumed Centrum Medyczne, Poznan
Washington University School of Medicine, St Louis
Baylor College of Medicine, Houston
Prof. Dr. med. Stephan Klebe, Freiburg im Breisgau
Rocky Mountain Movement Disorders Center, Englewood
Copernicus Podmiot Leczniczy sp. z o.o., Gdansk
Technische Universität München, München
Kbo-Isar-Amper-Klinikum gGmbH, Taufkirchen
Mayo Clinic Arizona, Phoenix
Mayo Clinic Arizona, Scottsdale
Universitätsklinikum Ulm, Ulm
Ronald Regan UCLA Medical Center Drug Information Center, Los Angeles
UCLA Neurology Clinic, Los Angeles
UCLA Radiology, Los Angeles
Friedrich-Alexander-Universität, Erlangen
University of California, Irvine, Irvine
Universitatsklinikum Wuerzburg, Würzburg
Massachusetts General Hospital, Charlestown
The Centre for Huntington Disease, Vancouver
Centre for Movement Disorders, Toronto
CHUM-Notre-Dame Hospital, Montreal
CHUM Notre Dame, Pharmacie, Montreal
Instytut Psychiatrii i Neurologii, Warsaw
NHS Grampian, Clinical Genetics Centre, Aberdeen
University Hospital Southampton NHS Foundation Trust, Southampton
Oxford University Hospitals NHS Trust, Oxford
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Birmingham & Solihull Mental Health NHS Foundation Trust, Birmingham
John Van Geest Centre for Brain Repair, Cambridge
University of Wales Hospital, Cardiff
NHS Greater Glasgow and Clyde, Glasgow
Clinical Research Facility, London
University College London Hospitals Huntington's Disease Research Centre, London
University College London Hospitals NHS Foundation Trust, London
Central Manchester University Hospitals NHS Foundation Trust, Manchester
The National Institute for Health Research/Wellcome Trust Clinical Research Facility, Manchester
St Nicholas Hospital, Newcastle upon Tyne
Newcastle Magnetic Resonance Centre, Newcastle upon Tyne
Lead Sponsor
Pfizer
INDUSTRY